Genetically-determined interaction between propafenone and low dose quinidine: role of active metabolites in modulating net drug effect (Q34397040)

1 August 2017

Genetically-determined interaction between propafenone and low dose quinidine: role of active metabolites in modulating net drug effect (English)

1 reference

1 August 2017

Christian Funck-Brentano

object named as

C Funck-Brentano

1

0 references

author name string

H K Kroemer

2

1 reference

1 August 2017

H Pavlou

3

1 reference

1 August 2017

R L Woosley

4

1 reference

1 August 2017

D M Roden

5

1 reference

1 August 2017

language of work or name

English

0 references

publication date

1 April 1989

1 reference

British Journal of Clinical Pharmacology

1 August 2017

1 reference

1 August 2017

27

1 reference

1 August 2017

4

1 reference

1 August 2017

435-444

1 reference

A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.

1 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1379722

Inhibitors of Cytochrome P-450s and their mechanism of action

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1379722

Renal organic anion transport system: pharmacological, physiological, and biochemical aspects.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1379722

Pharmacological studies on propafenone and its main metabolite 5-hydroxypropafenone.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1379722

Impaired oxidation of debrisoquine in patients with perhexiline liver injury

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1379722

Impaired oxidation of debrisoquine in patients with perhexiline neuropathy

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1379722

Metabolite cumulation during chronic propafenone dosing in arrhythmia.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1379722

Partial metabolic clearances as determinants of the oral bioavailability of propranolol

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1379722

Quinidine: potent inhibition of sparteine and debrisoquine oxidation in vivo.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1379722

Sparteine oxidation is practically abolished in quinidine-treated patients

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1379722

Enhanced antiarrhythmic efficacy of propafenone when used in combination with procainamide or quinidine.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1379722

Food increases the bioavailability of propafenone

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1379722

Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1379722

Induction of drug-metabolizing enzymes: mechanisms and consequences

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1379722

Severe complications of antianginal drug therapy in a patient identified as a poor metabolizer of metoprolol, propafenone, diltiazem, and sparteine

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1379722

Characterization of the common genetic defect in humans deficient in debrisoquine metabolism

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1379722

Electrophysiological effects of 5-hydroxypropafenone on guinea pig ventricular muscle fibers.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1379722

Defective N-oxidation of sparteine in man: A new pharmacogenetic defect

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1379722

Polymorphic hydroxylation of Debrisoquine in man.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1379722

Genetically determined polymorphisms in drug oxidation

6 July 2018

1 reference

Crossref

https://api.crossref.org/works/10.1111%2FJ.1365-2125.1989.TB05391.X

In vitro characterization of the human cytochrome P-450 involved in polymorphic oxidation of propafenone

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1111%2FJ.1365-2125.1989.TB05391.X

Competitive inhibition of sparteine oxidation in human liver by β-adrenoceptor antagonists and other cardiovascular drugs

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1111%2FJ.1365-2125.1989.TB05391.X

Oxidation phenotype--a major determinant of metoprolol metabolism and response

21 January 2018

1 reference

12 December 2020

Dextromethorphan as a safe probe for debrisoquine hydroxylation polymorphism

1 reference

12 December 2020

Effect of oxidative polymorphism (debrisoquine/sparteine type) on hepatic first-pass metabolism of bufuralol

1 reference

12 December 2020

Single-dose quinidine treatment inhibits metoprolol oxidation in extensive metabolizers

1 reference

12 December 2020

Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences

1 reference

12 December 2020

Extensive metabolizers of debrisoquine become poor metabolizers during quinidine treatment

1 reference

12 December 2020

Potent electrophysiologic effects of the major metabolites of propafenone in canine Purkinje fibers

1 reference

12 December 2020

The measurement of the Q-T interval of the electrocardiogram

1 reference

12 December 2020

Genetic control of isoniazid metabolism in man

1 reference

12 December 2020

Phenformin-induced lacticacidosis associated with impaired debrisoquine hydroxylation

1 reference

12 December 2020

Protecting poor metabolizers, a group at high risk of adverse drug reactions

1 reference

12 December 2020

10.1111/J.1365-2125.1989.TB05391.X

Identifiers

DOI

1 reference

1 August 2017

1 reference

1 August 2017

1 reference